z-logo
Premium
Hydrochlorothiazide‐induced photosensitivity in a psoriasis patient following exposure to narrow‐band ultraviolet B excimer therapy
Author(s) -
Rosenthal Amanda,
Herrmann Jennifer
Publication year - 2019
Publication title -
photodermatology, photoimmunology and photomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.736
H-Index - 60
eISSN - 1600-0781
pISSN - 0905-4383
DOI - 10.1111/phpp.12471
Subject(s) - photosensitivity , dermatology , medicine , psoriasis , hydrochlorothiazide , phototoxicity , rash , drug , ultraviolet therapy , ultraviolet , sunburn , excimer , optoelectronics , pharmacology , laser , materials science , chemistry , optics , biochemistry , blood pressure , in vitro , physics
Drug‐induced photosensitivity develops when the use of oral or topical photosensitizing medications creates a rash after exposure to ultraviolet ( UV ) radiation. Medications most commonly implicated in photosensitive drug reactions include amiodarone, nonsteroidal anti‐inflammatories, thiazides, tetracycline antibiotics, chlorpromazine, and fluoroquinolones. It is generally believed that drug‐induced photosensitivity is an UVA phenomenon, caused by UV wavelengths between 315 and 400 nm. Here, we present a case of hydrochlorothiazide ( HCTZ )‐induced photosensitivity following exposure to 308‐nm narrow‐band (nb) UVB light emitted from an excimer laser in a patient undergoing treatment for plaque psoriasis. This patient had received biweekly treatments with the excimer laser for years prior without any history of adverse reactions. We believe that our patient suffered an acute photosensitivity to UVB due to new‐onset HCTZ . Because nb UVB –emitting lasers are used to treat many dermatologic conditions, physicians should be aware of potential photosensitivity reactions, review medication lists and counsel patients accordingly.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here